Ceramides Mixture
Based on 2 publication(s) in Google Scholar
Ceramides Mixture is an endogenous ceramide and consists of hydroxy and non-hydroxy fatty acid-containing ceramides. Ceramides Mixture is a main lipid component of the permeability barrier in epidermis. Ceramides Mixture is involved in the regulation of growth inhibition, cell cycle arrest, and modulation of telomerase activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.8%
- CAS No.: 100403-19-8
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ceramides Mixture
More
Customer Validation & Images
-
IF
-
2D/3D Cell Culture and Differentiation
-
Cell Proliferation/Viability Assay
-
Apoptosis Analysis
-
ELISA
Activité biologique
Endogenous Ceramides (generated in response to bacterial sphingomyelinase overexpression or daunorubicin treatment) inhibits mRNA synthesis of telomerase reverse transcriptase and telomerase activity via inactivation of c-Myc transcription factor in the A549 human lung adenocarcinoma cell line[1].
The sustained generation of long chain endogenous ceramide requires the biochemical recycling of the sphingosine backbone of C6-ceramide, which involves deacylation and reacylation of ceramide for the generation of endogenous long chain ceramide (mainly C16:0- and C24:1-Ceramides), most likely by CoA-dependent ceramide synthase, which is inhibited by fumonisin B1. In A549 cells the generation of long chain endogenous ceramide mediates the effects of exogenous C6-ceramide on growth inhibition, cell cycle arrest, and the modulation of telomerase activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 100403-19-8
-
Appearance Solid
-
Color White to light yellow
-
SMILES
[Ceramides Mixture]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
ACS Cent Sci
Astragaloside IV Alleviates Fructose-Induced Intestinal Metabolic Senescence by Targeting Ketohexokinase Asn261/Ala226 to Preserve Intestinal Stem Cell Homeostasis. [Abstract]2025 Jul 29;11(9):1682-1699. PMID: 41019116
Ceramides Mixture purchased from MedChemExpress. Usage Cited in: ACS Cent Sci. 2025 Jul 29;11(9):1682-1699. [Abstract]
Representative immunofluorescence images of OLFM4 (green) in intestinal organoids under Ceramides Mixture (Ceramide) (10 μg/mL; 48 h) and ceramide+AS-IV (5 μM; 48 h) treatments.
Ceramides Mixture purchased from MedChemExpress. Usage Cited in: ACS Cent Sci. 2025 Jul 29;11(9):1682-1699. [Abstract]
Representative images of intestinal organoids treated with Ceramides Mixture (Ceramide) (10 μg/mL; 48 h) or ceramide with AS-IV (ceramide+AS-IV (5 μM; 48 h)).
-
EMBO Mol Med
BCAA insufficiency leads to premature ovarian insufficiency via ceramide-induced elevation of ROS. [Abstract]2023 Apr 11;15(4):e17450. PMID: 36847712
Ceramides Mixture purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2023 Apr 11;15(4):e17450. [Abstract]
The relative cell viability of KGN cells with Ceramides Mixture (Cer, 30-60 μM; 48 h) treatment. N = 6.
Ceramides Mixture purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2023 Apr 11;15(4):e17450. [Abstract]
The percentage of Annexin V positive cells of KGN cells with Ceramides Mixture (Cer, 40 μM; 48 h) treatment. N = 3
Ceramides Mixture purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2023 Apr 11;15(4):e17450. [Abstract]
Decreases of E2 secretions from KGN cells treated with Ceramides Mixture (Cer, 30-60 μM; 48 h). N = 3.
Solvant et solubilité
DMSO : 1 mg/mL (ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.1 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 0.1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (1.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.1 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 0.1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (1.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (269 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ogretmen B, et al. Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide in the A549 human lung adenocarcinoma cell line. Role for endogenous ceramide in mediating the action of exogenous ceramide. J Biol Chem. 2002 Apr 12;277(15):12960-9. [Content Brief]
[2]. Macheleidt O, et al. Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol. 2002 Jul;119(1):166-73. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ceramides Mixture Related Classifications
HY-113679 Related Classifications
Powered by Bioz